VY NAV01 / Voyager - LARVOL DELTA

Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results (Businesswire) - "Announced Nav1.7 to treat chronic neuropathic pain as flagship program in Sangamo’s newly prioritized wholly owned neurology pipeline, with an IND submission expected in 2024. First data from this program expected to be published via a platform presentation at the upcoming American Society for Cell and Gene Therapy (ASGCT) 26th Annual Meeting in Los Angeles in May 2023. Advanced wholly owned prion disease program, with an IND submission anticipated in 2025."

IND • CNS Disorders • Pain